Navigation Links
Development of new anti-cancer gene therapy approach using lentiviral vectors
Date:3/29/2010

Neuherberg, March 29, 2010. Helmholtz Zentrum Mnchen has launched a new cooperative project with SIRION BIOTECH GmbH in Martinsried to develop new therapeutic approaches against lymphoid tumors. With a two-year grant from the Federal Ministry for Economics and Technology, the two partners will seek to further develop lentiviral vector systems to better understand the disease mechanisms of this cancer form and to devise approaches for treatment.

The future of gene therapy approaches in cancer treatment is especially dependent on the quality of the vectors involved in the regulation of gene expression in the tumor cells. Lentiviruses are a very promising vector system for this they even reach difficult-to-access cell types such as the hematopoietic cells of the blood-forming system.

With their new research cooperation Helmholtz Zentrum Mnchen and SIRION BIOTECH seek to optimize the use of lentiviruses as gene vectors for hematopoietic cells. Over the long term this may result in an important step forward in the therapy of malignant lymphomas. The Federal Ministry for Economics and Technology is funding the project over the next two years with approximately 500,000 euros.

"We quite consciously decided on a cooperation partner from the biotech sector," said Professor Gnther Wess, scientific-technical director of Helmholtz Zentrum Mnchen. "The symbiosis of our scientific expertise in the field of lentiviruses with the technical know-how of SIRION BIOTECH promises to yield valuable insights about the molecular disease mechanisms and the function of disease-relevant genes in the blood cells."

Dr. Nataa Anastasov, who is in charge of the project at the Institute of Radiation Biology of Helmholtz Zentrum Mnchen, and her colleagues from SIRION BIOTECH already have concrete ideas regarding the new generation of lentiviruses: "We want to specifically refine the lentiviral vectors to target the tumor cell markers." To achieve this, the researchers first want to develop new cell lines in the laboratory with improved binding characteristics for virus production.

"We are very pleased that Helmholtz Zentrum Mnchen has chosen to cooperate with our company due to our specialization in genetically modified cells and viral vector technologies," said Dr. Jrgen Flach, CEO of SIRION BIOTECH. Both cooperation partners are confident that over the long term they can make an important contribution to the treatment of lymphomas.


'/>"/>

Contact: Sven Winkler
presse@helmholtz-muenchen.de
49-898-931-873-946
Helmholtz Zentrum Mnchen - German Research Center for Environmental Health
Source:Eurekalert

Related biology news :

1. Compound screening for drug development made simpler
2. Quickly and easily integrate fingerprint biometric features into portable applications with Texas Instruments comprehensive, low cost fingerprint development kit
3. Chemists influence stem-cell development with geometry
4. Opposing functions of a key molecule in the development of organisms
5. Development of more muscular trout could boost commercial aquaculture
6. Sonic hedgehog gene found in an unexpected place during limb development
7. Model may offer better understanding of embryonic development
8. Chemical competition: Research identifies new mechanism regulating embryonic development
9. ACS webinar features developments in online water and wastewater monitoring
10. Rondaxe and TD2 form strategic drug development alliance
11. Zebrafish swim into drug development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2017)... 2017 Former 9/11 Commission border counsel and ... Janice Kephart of Identity Strategy Partners, LLP, today ... "Executive Order: Protecting the Nation From Foreign Terrorist ... "As President Trump,s ,Travel Ban, Executive Order gains ... banned the travel ban, it is important that our ...
(Date:2/8/2017)... , Feb. 8, 2017 About Voice Recognition ... to match it against a stored voiceprint template. ... pitch, cadence, and tone are compared to distinguish ... hardware installation, as most PCs already have a ... transactions. Voice recognition biometrics are most likely to ...
(Date:2/8/2017)... Feb. 7, 2017 The biometrics market ... the confluence of organizations, desires to better authenticate ... systems (password and challenge questions), biometrics is quickly ... systems. The market is driven by use cases, ... consumer and enterprise uses cases, with consumer-facing use ...
Breaking Biology News(10 mins):
(Date:2/22/2017)... SAN DIEGO , Feb. 22, 2017 /PRNewswire/ ... today expansion of its translational research program using ... establishment of laboratory facilities in San Diego.  The ... Diego BioLabs facility, a biotechnology incubator sponsored by ... In November 2016, the Company obtained ...
(Date:2/21/2017)... , Feb. 21, 2017 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or ... operational results for the three months ended December 31, 2016. ... -based life sciences and diagnostics company that develops and commercializes ... ... to build on the commercial milestones achieved in fiscal 2016," ...
(Date:2/21/2017)... Basel, Switzerland (PRWEB) , ... February 21, 2017 ... ... for biopharmaceutical and biotech research and development (R&D), today announced the establishment of ... headed by Managing Director Kevin Teburi, a recognized expert in life science informatics. ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... will pair its $200M operational capacity with its strategic internal leadership to ... areas affecting quality and operational management. With office locations in North ...
Breaking Biology Technology: